Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms

Autor:	Karla Rodriguez-Lopez, Lea Dutta, Howard Gurney, Thomas E. Hutson, Avivit Peer, Robert J. Motzer, Dongyuan Xing, Masatoshi Eto, Anna Alyasova, Hilary Glen, Sun Young Rha, Thomas Powles, Viktor Grünwald, Camillo Porta, Jaime R. Merchan, Toshio Takagi, Toni K. Choueiri, Manuela Schmidinger, Ulka N. Vaishampayan, Ugo De Giorgi
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty Everolimus Sunitinib business.industry Medizin medicine.disease chemistry.chemical_compound chemistry Renal cell carcinoma Internal medicine Post-hoc analysis medicine Lenvatinib business Objective response medicine.drug
Zdroj:	Journal of Clinical Oncology. 39:4562-4562
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2021.39.15_suppl.4562
Popis:	4562 Background: The multicenter, open-label, randomized, phase 3 CLEAR study showed that LEN + EVE had a significant PFS benefit (HR 0.65, 95% CI 0.53-0.80, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4833dbdde1ed066a90e5968b3386a02b https://doi.org/10.1200/jco.2021.39.15_suppl.4562 Zobrazit plný text záznamu